Protagonist Therapeutics (PTGX) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Materials Nature Offset Package Pandemic Raw Materials Toxic Waste Access African American Asian Benefits Black Collective Bargaining Community Customer Data Privacy Data Security Death Demographics Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnic Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Injury Latinx LGBTQ Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workforce Assessment Assurance Audit Board Refreshment Bonus Chronic Classified Classified Board Commitment Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Purpose R&D Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Self-evaluation Stockholder Engagement Strategy Targets Tax Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

At the Protagonist Therapeutics, Inc. (the “Company”) 2022 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 26, 2022, the stockholders voted on the four proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 13, 2022. The results of the matters voted upon at the Annual Meeting were:

Proposal 1 — To elect the two Class III directors named below to serve until the 2025 Annual Meeting of Stockholders. Each of the two named nominees was so elected, with the votes thereon as follows:

Nominees	For
	Final Voting Results
Harold E. Selick, Ph.D.		27,907,944	8,361,194	2,405,334
Bryan Giraudo		28,108,252	8,160,886	2,405,334

Proposal 2 — To approve, on an advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows:

For				Against				Abstain				Broker Non-Votes
Final Voting Results
	35,832,587				413,371				23,180				2,405,334

Proposal 3 — To recommend, by non-binding vote, the frequency of future executive compensation votes. The votes on this proposal were as follows:

Final Voting Results
1 Year		2 Years		3 Years		Abstain		Broker Non-Votes
	35,578,366		4,924		683,401		2,447		2,405,334

Considering the strong support for an annual vote as reflected in the voting results, the Company intends to hold future advisory votes to approve executive compensation annually until the matter is again submitted to the Company’s stockholders for a vote.

Proposal 4 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. This proposal was approved by the requisite vote, with the votes thereon as follows:

For				Against				Abstain				Broker Non-Votes
Final Voting Results
	38,667,405				5,575				1,492				--

No other matters were submitted for stockholder action.